share_log

康希诺(688185.SH):重组脊髓灰质炎疫苗于印度尼西亚获得临床试验批准

cansino biologics inc. (688185.SH): The recombinant polio vaccine has obtained clinical trial approval in Indonesia.

Gelonghui Finance ·  Oct 9 04:16

Cansino Biologics Inc. announced on October 9th that the company's recombinant polio vaccine has recently received clinical trial approval from the Food and Drug Administration of India (Badan Pengawas Obat dan Makanan, Republik Indonesia, "BPOM"). The phase I/II clinical trial of the recombinant polio vaccine is intended to further evaluate its safety and immunogenicity after vaccination in infants and young children of specific ages.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment